Showing 71-80 of 747 results for "".
- New Survey: AD Is More Than Skin Deephttps://practicaldermatology.com/news/new-survey-ad-is-more-than-skin-deep/2458417/American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as New York dermatologist Doris Day, MD, who notes that some of the results of the large suvey w
- The La Roche-Posay North American Foundation Awards 2016 Grant Winnershttps://practicaldermatology.com/news/the-la-roche-posay-north-american-foundation-awards-2016-grant-winners/2458530/Committed to working alongside dermatologists, La Roche-Posay's North American Fondation encourages residents, fellows and practitioners with at least two years beyond training to develop innovative programs. The brand and a board of certified dermatologists awards two to three w
- Untreated Sleep Apnea Linked to Melanoma Aggressionhttps://practicaldermatology.com/news/untreated-sleep-apnea-linked-to-melanoma-aggressiveness/2458564/Untreated severe obstructive sleep apnea (OSA) is linked to increased aggressiveness of malignant cutaneous melanoma, according to research presented at the American Thoracic Society 2016 International Conference in San Francisco. The study involved 412 patients, average age 55.8, w
- First Ever SkinCeuticals Aesthetic Center for Men Opens in DChttps://practicaldermatology.com/news/first-ever-skinceuticals-aesthetic-center-for-men-opens-in-dc/2458654/SkinCeuticals cut the ribbon on their first ever brick-and-mortar Center for men in Washington, DC. The SkinCeuticals Aesthetic Center is located within W for Men at the Washington Institute of Dermatologic Laser Surgery. "Men are increasingly interested in looking and
- FDA Approves Cotellic Combined with Zelboraf to Treat Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-cotellic-combined-with-zelboraf-to-treat-advanced-melanoma/2458819/The FDA approved Cotellic (cobimetinib) to be used in combination with Zelboraf (vemurafenib) to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation). Cotellic w
- Chief Academy Convenes in San Antoniohttps://practicaldermatology.com/news/chief-academy-convenes-in-san-antonio/2458938/The 2015 Chief Academy convened this month on the campus of the University of Texas Health Science Center - San Antonio, marking a move for the meeting from its 7-year home in Chicago. Dr. Vineet Mishra, Director of Mohs Surgery and Procedural Dermatology as w
- LEO Pharma Submits NDA for Aerosol Foam for Psoriasis to FDAhttps://practicaldermatology.com/news/leo-pharma-submits-nda-for-aerosol-foam-for-psoriasis-to-fda/2459033/LEO Pharma has submitted a New Drug Application to FDA for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. The novel aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed w
- Advanced Dermatology & Cosmetic Surgery, (ADCS Clinics) Acquires Lakeland Dermatology, Inc.https://practicaldermatology.com/news/20130906-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_lakeland_dermatology_inc/2459467/ADCS Clinics (“ADCS”) has completed the acquisition of Dr. David W. Murray's, dermatology practice located in Lakeland, Florida. Dr. Murray is Board-Certified - trained at the University of Oregon Health Sciences Center and did his residency at the Naval Hospital in San Diego. He spent 11 years in a
- Modern Aesthetics Launches from Bryn Mawr Communicationshttps://practicaldermatology.com/news/20130228-modern_aesthetics_launches_from_bryn_mawr_communications/2459603/The debut issue of Modern Aesthetics (www.modernaesthetics.com), a publication dedicated to coverage of minimally invasive cosmetic procedures and targeting Plastic Surgeons, Facial Plastic Surgeons, Oculoplastic Surgeons, and Dermatologists, has been released by Bryn Mawr Communications III, LLC. W
- Valeant Acquires Medicis Pharmaceutical Corp. for $2.6 Billionhttps://practicaldermatology.com/news/20120904-valeant_acquires_medicis_pharmaceutical_for_26_billion/2459743/Valeant Pharmaceuticals announced an agreement to acquire Medicis Pharmaceutical for $44 per share in cash, in a deal worth approximately $2.6 billion. The transaction is expected to close in the first half of 2013 and has been approved by each company's board of directors. The combined operations w